ArticleHuman vaccines & immunotherapeutics2021
Experimental studies using OMV in a new platform of SARS-CoV-2 vaccines.
Article in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients.Scientific reports · 2021Trial
- Bacterial Membrane Vesicles as Versatile Platforms for Systemic and Mucosal Vaccines.Vaccines · 2026Review
- Bioengineering Outer-Membrane Vesicles for Vaccine Development: Strategies, Advances, and Perspectives.Vaccines · 2025Review
- Hybrid response to SARS-CoV-2 andHuman vaccines & immunotherapeutics · 2024Article
- Bacterial Membrane Vesicles as a Novel Vaccine Platform against SARS-CoV-2.Current microbiology · 2024Review
- Vaccine Strategies to Elicit Mucosal Immunity.Vaccines · 2024Review
- The Two Faces of Bacterial Membrane Vesicles: Pathophysiological Roles and Therapeutic Opportunities.Antibiotics (Basel, Switzerland) · 2023Review
- Article
- Review
- COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges.Human vaccines & immunotherapeutics · 2022Review
- Outer Membrane Vesicles: An Emerging Vaccine Platform.Vaccines · 2022Review
- Protein-protein conjugation enhances the immunogenicity of SARS-CoV-2 receptor-binding domain (RBD) vaccines.iScience · 2022Article
- Biological Nanoparticles in Vaccine Development.Frontiers in bioengineering and biotechnology · 2022Review
- SARS-CoV-2 vaccines: Potential refinements through induction of mucosal and trained immunity.Clinics (Sao Paulo, Brazil) · 2022Article
- Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview.Vaccines · 2021Review
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although COVID-19 vaccines have recently been approved for emergency use, search for new vaccines are still urgent, since the access of the countries, especially the poorest, to the vaccines, has shown to be slower than the necessary to rapidly control the pandemic. We proposed a novel platform for vaccine using recombinant receptor binding domain (rRBD) from Sars-Cov-2 spike protein and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.